Next Article in Journal / Special Issue
Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Previous Article in Journal
Speciation in Metal Toxicity and Metal-Based Therapeutics
Previous Article in Special Issue
Taxane-Induced Peripheral Neurotoxicity
Article Menu

Export Article

Open AccessReview
Toxics 2015, 3(2), 187-197; doi:10.3390/toxics3020187

Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN)

Department of Neurology, “Saint Andrew’s” General Hospital of Patras, Patras 26335, Greece
Academic Editors: Guido Cavaletti and Valentina Carozzi
Received: 3 May 2015 / Revised: 20 May 2015 / Accepted: 26 May 2015 / Published: 29 May 2015
(This article belongs to the Special Issue Toxicities of Therapeutic Agents Used in Medicine)
View Full-Text   |   Download PDF [315 KB, uploaded 29 May 2015]   |  

Abstract

Oxaliplatin-induced peripheral neuropathy (OXAIPN) is of great clinical interest as it ranks among the most common dose limiting toxicities of oxaliplatin (OXA) administration with an obvious impact on the outcome of cancer patients. In addition, OXAIPN has a detrimental effect on the quality of life of cancer patients because it can be long lasting or even permanent. It has a unique spectrum of clinical presentation, being manifested with two distinct syndromes: the acute neurotoxicity that appears soon after OXA administration and is usually transient, and the chronic cumulative syndrome that resembles the characteristics of all platinum compounds. Despite advances in research in relation to the elucidation of the true OXAIPN pathogenesis, characteristics and management, there are still several open issues to be addressed. One of the most important open issues is to determine reliable biomarkers to allow prompt identification of patients at high risk to develop OXAIPN and towards this view well designed genome wide analyses are warranted to adequately address this gap in knowledge. Recent updates are provided in this article in relation to the pathogenesis, clinical characteristics, pharmacogenetics and management of OXAIPN. View Full-Text
Keywords: chemotherapy; oxaliplatin; peripheral neurotoxicity; incidence; characteristics; pharmacogenetics chemotherapy; oxaliplatin; peripheral neurotoxicity; incidence; characteristics; pharmacogenetics
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Argyriou, A.A. Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN). Toxics 2015, 3, 187-197.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxics EISSN 2305-6304 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top